The single most important factor limiting the growth of neurotherapeutic drug development is the blood-brain barrier (BBB). It has been reported that approximately 98% of small molecules and nearly all large therapeutic molecules, such as monoclonal antibodies,...
Approved drugs can be administered via many routes of administration, including oral, intravenous, intramuscular, subcutaneous, sublingual, topical, intranasal, intraperitoneal, intrathecal, rectal, vaginal, intraarticular, and intraocular delivery. Different drug...
Hepatic drug metabolism involves enzymatic reactions, including oxidation, reduction, and hydrolysis, which modify the drug q molecule and make it more water-soluble, allowing it to be excreted more easily. The main enzymes involved in drug metabolism are called...
As a drug development sponsor, you know that creating a Clinical Study Report (CSR) is a critical part of the drug development process. It is a crucial component for regulatory agencies when determining whether to approve a drug for market. However, creating a...
In the world of clinical research, accelerated drug development can be a tedious process, taking over 10 years for medications to get to market. From bench to bedside, pharmaceutical companies invest millions of dollars, and delays in drug development cost thousands...
Renal impairment is a common comorbidity for patients because of the disease itself, toxicity of treatments, or because of other factors affecting organ function, such as increased age. Drugs are normally cleared from the human body by a number of routes, each of...
